Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "cardiovascular-disease"

117 News Found

Shanghai Argo announces multi-program RNAi licenses with Novartis
News | January 11, 2024

Shanghai Argo announces multi-program RNAi licenses with Novartis

Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.


Medway Hospitals raises US$5 million in a financing round led by Kyra Ventures
News | January 04, 2024

Medway Hospitals raises US$5 million in a financing round led by Kyra Ventures

Medway setup a state-of-the-art Heart Institute in Chennai


Glenmark to launch biosimilar of anti-diabetic drug Liraglutide in India
News | January 03, 2024

Glenmark to launch biosimilar of anti-diabetic drug Liraglutide in India

Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs


Cell and gene therapy will be top industry trend for pharma in 2024, finds GlobalData
News | January 02, 2024

Cell and gene therapy will be top industry trend for pharma in 2024, finds GlobalData

The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year


Digital transformation key to managing rising organisational healthcare costs in India
Digitisation | December 22, 2023

Digital transformation key to managing rising organisational healthcare costs in India

Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024


Zepbound is now available in US for adults living with obesity
News | December 09, 2023

Zepbound is now available in US for adults living with obesity

Express Scripts to add Zepbound to National Preferred Formulary


Lupin receives tentative approval from USFDA for Canagliflozin Tablets
Drug Approval | November 24, 2023

Lupin receives tentative approval from USFDA for Canagliflozin Tablets

Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor


Lupin receives USFDA tentative approval for Canagliflozin and Metformin Hydrochloride ER Tablets
Drug Approval | November 08, 2023

Lupin receives USFDA tentative approval for Canagliflozin and Metformin Hydrochloride ER Tablets

This product will be manufactured at Lupin’s Pithampur facility in India


Zydus announces IND clearance of a novel Anti-PCSK9 candidate
Diagnostic Center | October 03, 2023

Zydus announces IND clearance of a novel Anti-PCSK9 candidate

Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity


Apollo Hospitals celebrates its leadership position as the largest Cardiac care programme in India
Healthcare | September 29, 2023

Apollo Hospitals celebrates its leadership position as the largest Cardiac care programme in India

Apollo's unparalleled clinical excellence is built on extensive experience of performing over 300,000 angioplasties and 200,000 cardiac surgeries